Home>Topics>Companies>Bristol-Myers Squibb

Bristol-Myers Squibb BMY

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. UPDATE 1-Europe pushes back verdict on Bristol immune system cancer drug

      Headlines

      Fri, 27 Mar 2015

      LONDON, March 27 (Reuters) - European regulators have postponed a decision on whether to recommend approval of a closely watched Bristol - Myers Squibb drug that helps the immune system fight cancer, officials said on Friday.

    2. Europe postpones decision on Bristol immune system cancer drug

      Headlines

      Fri, 27 Mar 2015

      LONDON, March 27 (Reuters) - European regulators have postponed a decision on whether to recommend approval of a closely watched Bristol - Myers Squibb drug that helps the immune system fight cancer, a...

    3. New Cancer Drugs: First Movers Will Win

      Video Reports

      Fri, 27 Mar 2015

      well in combination, are really going to be the long-term winners. The way we currently see it now is that Bristol - Myers Squibb ( BMY ) is the best positioned and is currently the first mover in this space. They are followed closely by Merck

      Bristol-Myers Squibb found at 1:27

      the long-term winners. The way we currently see it now is that Bristol-Myers Squibb ( BMY ) is the best positioned and is currently the first mover in this space. They are followed closely by Merck (MRK). And we
    4. Bristol - Myers buys rights to Novo Nordisk immune system project

      Headlines

      Tue, 24 Mar 2015

      March 24 (Reuters) - Bristol - Myers Squibb said on Tuesday it had agreed to acquire rights to a Novo Nordisk immune system research programme, which the Danish company is divesting as it focuses...

    5. Actavis' Wide-Moat Transformation Offers Shareholder Rewards

      Headlines

      Mon, 23 Mar 2015

      to one of the largest specialty pharmaceutical companies, with sales on par with peers like Eli Lilly LLY and Bristol - Myers Squibb BMY . Only a few years ago, Watson was a U.S.-centric generic drug manufacturer with less global scale and

    6. Bristol , Sanofi and Novartis drugs to shine among 2015 launches

      Headlines

      Mon, 23 Mar 2015

      LONDON, March 23 (Reuters) - Bristol - Myers Squibb , Sanofi and Novartis have the three top new drugs set to reach the market in 2015, among 11 products each with $1 billion-plus sales potential, according to a Thomson Reuters analysis.

    7. UPDATE 1-FDA to review re-submitted Bristol - Myers hepatitis C drug

      Headlines

      Thu, 12 Mar 2015

      March 12 (Reuters) - U.S. regulators have accepted Bristol - Myers Squibb Co 's re-submitted marketing application for an experimental hepatitis C treatment after the drugmaker was forced last year to withdraw its initial request.

    8. FDA to review re-submitted Bristol - Myers hepatitis C drug

      Headlines

      Thu, 12 Mar 2015

      March 12 (Reuters) - Bristol - Myers Squibb Co said U.S. regulators have accepted the company's re-submitted marketing application for an experimental treatment for hepatitis C, following the drugmaker's decision last year to pull back its initial marketing request.

    9. UPDATE 1-U.S. FDA approves Bristol - Myers immunotherapy for lung cancer

      Headlines

      Wed, 4 Mar 2015

      March 4 (Reuters) - U.S. health regulators on Wednesday swiftly approved a Bristol - Myers Squibb Co drug that helps the immune system fight the most common form of lung cancer, sending the company's...

    10. US FDA approves Bristol - Myers immunotherapy for lung cancer

      Headlines

      Wed, 4 Mar 2015

      March 4 (Reuters) - U.S. health regulators on Wednesday approved Bristol - Myers Squibb Co 's drug, Opdivo, which helps the immune system fight cancer, to treat squamous non-small cell lung cancer once the disease has progressed following platinum-based chemotherapy.

    « Prev12345Next »
    Content Partners